Raloxifene: a review of its use in the prevention of invasive breast cancer (Q37263209)

19 August 2017

1 reference

title

Raloxifene: a review of its use in the prevention of invasive breast cancer (English)

1 reference

19 August 2017

1 reference

2

Gillian M Keating

1 reference

19 August 2017

Marit D Moen

1

1 reference

19 August 2017

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

68

1 reference

19 August 2017

2059-2083

1 reference

19 August 2017

14

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868140-00008

19 August 2017

0 references

cites work

Raloxifene pharmacokinetics in males with normal and impaired renal function

1 reference

12 December 2020

Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.

1 reference

12 December 2020

1 reference

12 December 2020

Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells

1 reference

12 December 2020

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action

1 reference

12 December 2020

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

The rise of raloxifene and the fall of invasive breast cancer

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women

1 reference

12 December 2020

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

1 reference

12 December 2020

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients

1 reference

12 December 2020

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

1 reference

12 December 2020

Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene

1 reference

12 December 2020

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk

1 reference

12 December 2020

NCI director opts against breast cancer prevention trial in favor of biomarkers

1 reference

12 December 2020

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

1 reference

12 December 2020

Raloxifene in breast cancer prevention

1 reference

12 December 2020

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

1 reference

12 December 2020

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

1 reference

12 December 2020

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1 reference

12 December 2020

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

1 reference

12 December 2020

Raloxifene and the prevention of breast cancer

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

1 reference

12 December 2020

Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo

1 reference

12 December 2020

Cognitive function in postmenopausal women treated with raloxifene

1 reference

12 December 2020

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

1 reference

12 December 2020

Raloxifene and estrogen: comparative bone-remodeling kinetics

1 reference

12 December 2020

Interest in breast cancer chemoprevention among older women

1 reference

12 December 2020

Safety assessment of raloxifene over eight years in a clinical trial setting

1 reference

12 December 2020

Pharmacokinetics of selective estrogen receptor modulators

1 reference

12 December 2020

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

12 December 2020

Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia

1 reference

12 December 2020

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

1 reference

12 December 2020

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

Women's interest in chemoprevention for breast cancer

1 reference

12 December 2020

Validating and improving models for projecting the absolute risk of breast cancer

1 reference

12 December 2020

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

12 December 2020

Selective estrogen receptor modulators and prevention of invasive breast cancer

1 reference

12 December 2020

Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice

1 reference

12 December 2020

Assessing breast cancer risk: evolution of the Gail Model

1 reference

12 December 2020

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

1 reference

12 December 2020

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

1 reference

12 December 2020

Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method

1 reference

12 December 2020

Beyond raloxifene for the prevention of osteoporosis and breast cancer

1 reference

12 December 2020

Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta

1 reference

12 December 2020

Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women

1 reference

12 December 2020

A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium

1 reference

12 December 2020

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

1 reference

12 December 2020

A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women

1 reference

12 December 2020

Pharmacokinetics of raloxifene and its clinical application

1 reference

12 December 2020

Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study

1 reference

12 December 2020

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer

1 reference

12 December 2020

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

1 reference

12 December 2020

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Raloxifene: a review of its use in postmenopausal osteoporosis

1 reference

12 December 2020

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00003495-200868140-00008

Identifiers

DOI

1 reference

PubMed ID

18778124

Dimensions Publication ID

19 August 2017

0 references

1 reference

PubMed ID

18778124